June 3rd 2024
In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.
Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.
June 2nd 2024
Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.
Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo in limited-stage small cell lung cancer.
Neoadjuvant nivolumab/ipilimumab followed by TLND and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death in melanoma.
June 1st 2024
Induction encorafenib/binimetinib before nivolumab/ipilimumab did not improve PFS in unresectable or metastatic BRAF V600E/K–positive melanoma.
May 30th 2024
Adding atezolizumab to neoadjuvant pertuzumab, trastuzumab, and chemotherapy produced improved EFS and DFS rates in HER2-positive early breast cancer.
May 29th 2024
The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.
May 22nd 2024
Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.
Michelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.
May 21st 2024
The FDA has updated the PDUFA target action date for the BLA for subcutaneous nivolumab in advanced or metastatic solid tumors.
May 20th 2024
Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.
May 17th 2024
Jorge J. Nieva, MD, details the benefits of telemedicine and a first-of-its-kind clinical trial where patients with NSCLC will receive subcutaneous immunotherapy at home.
May 14th 2024
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
Relatlimab plus nivolumab and chemotherapy did not improve responses in untreated advanced gastric or GEJ cancer with a LAG-3 expression of at least 1%.
May 10th 2024
Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.
First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.
May 7th 2024
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.
May 1st 2024
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
April 24th 2024
The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.
